Epigenetic Screening for Paternal Age Risks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Advanced paternal age is associated with increased risks of adverse outcomes during embryogenesis, including birth defects and neurodevelopmental disorders such as autism spectrum disorder, schizophrenia, and bipolar disorder, due to epigenetic dysregulation, but existing technologies lack effective methods for identifying and mitigating these risks.
Innovation Solution
Methods and kits for identifying epigenetic dysregulation in blastocysts and sperm, specifically through DNA methylation analysis of candidate genes, to screen for and rank embryos or sperm based on their epigenetic status, allowing for the selection of healthier samples for implantation or fertilization, thereby reducing the risk of adverse outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If advanced paternal age is accepted without screening, then family planning is simple and accessible, but the risk of epigenetic dysregulation and adverse outcomes increases
Solution Approach 1:
The patent segments the epigenetic screening process into distinct components: (1) obtaining biological samples (sperm or blastocyst), (2) performing DNA methylation analysis on specific candidate genes, (3) comparing methylation levels to reference ranges, and (4) making clinical decisions based on results. This segmentation makes the complex screening process more manageable and implementable in clinical settings.
Solution Approach 2:
The patent applies preliminary action by performing epigenetic screening before implantation or fertilization decisions are made. By assessing DNA methylation levels in advance, clinicians can identify embryos or sperm with epigenetic dysregulation and prevent their use, thereby avoiding potential adverse outcomes before they occur.
2Measurement precision
If comprehensive epigenetic screening is performed on all samples, then the accuracy of identifying adverse risks improves, but the cost and time required for screening increases
Solution Approach 1:
The patent applies local quality by focusing DNA methylation analysis on specific candidate genes associated with neurodevelopmental disorders (such as autism spectrum disorder, schizophrenia, and bipolar disorder) rather than performing genome-wide screening. This targeted approach maintains high measurement precision for clinically relevant genes while significantly reducing the time and computational resources required compared to comprehensive screening.
Solution Approach 2:
The patent implements partial action by screening only a selected panel of candidate genes rather than the entire genome. This partial screening approach provides sufficient accuracy for clinical decision-making regarding epigenetic risk while avoiding the excessive time and resource requirements of complete genomic analysis.
3Reliability
If DNA methylation analysis is performed on multiple candidate genes, then the ability to detect epigenetic dysregulation improves, but the complexity of the testing procedure increases
Solution Approach 1:
The patent applies universality by developing a multi-functional screening system that can analyze DNA methylation levels across multiple candidate genes using a single integrated approach. The same analytical methodology and reference ranges can be applied to various genes associated with different neurodevelopmental disorders, making the testing procedure more efficient and less complex than performing separate specialized tests for each gene or disorder.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed methods enable the identification of epigenetic dysregulation associated with adverse outcomes, allowing for the selection of healthier embryos or sperm, potentially reducing the incidence of neurodevelopmental disorders in offspring by excluding samples with abnormal methylation patterns.
Implementation Method 1
identifying DNA methylation errors in the blastocyst. An increased risk of adverse outcome is correlated to epigenetic dysregulation in a blastocyst, sperm, or sperm population having global DNA with an overall hypomethylated shift
Data Source
AI summary
Methods and kits for the identification and screening of epigenetic dysregulation in a blastocyst, sperm, or sperm population are provided. Identification and screening of epigenetic dysregulation is particularly tied to a number of candidate genes, termed autism spectrum disorder genes, schizophrenia genes, bipolar disorder genes, or opioid signaling pathway genes.